PerkinElmer Life and Analytical Sciences   
Wallac Oy   
P.O. Box 10   
FIN-20101 Turku, Finland   
Phone: +358 - (0)2 - 267 8111   
Fax: +358 - (0)2 - 267 8357   
http://www.perkinelmer.com

# 510(k) Summary

# Introduction

This summary of $5 1 0 ( \mathrm { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

<table><tr><td colspan="2">The assigned 510 (k) number is k071649</td></tr><tr><td></td><td></td></tr><tr><td>Submitter Name Address</td><td>Wallac Oy</td></tr><tr><td></td><td>Mustionkatu 6 20750 Turku, Finland</td></tr><tr><td></td><td></td></tr><tr><td>Phone Fax</td><td>+358-2-2678575</td></tr><tr><td></td><td>+358-2-2678357</td></tr><tr><td>Contact Person</td><td>1 elena Lundström</td></tr><tr><td>Date of Preparation July 31, 2008</td><td>Registration Manager</td></tr><tr><td></td><td></td></tr><tr><td>Device name</td><td>Trade Name Neonatal Total Galactose Kit</td></tr><tr><td>Common Name</td><td>Enzymatic Methods, galactose</td></tr><tr><td>Classification Name</td><td>Galactose Test System (21 CFR 862.1310) Class I</td></tr><tr><td>Product Code</td><td>JIA</td></tr></table>

#

edicate device BioRad Quantase™ Neonatal Total Galactose Screening Assay (k990654)

# Description of the device

The Neonatal Total Galactose kit makes use of a fluorescent galactose oxidase method. The assay measures total galactose, i.e. both galactose and galactose-1-phosphate. The following schematic summarizes the reactions that occur during the test procedure:

![](images/2d1ea5e2772b93b756c82fc16c643819596c27b6ab755395d1ddfadab717ca81.jpg)

The fluorescence can be measured using an excitation central wavclength of $3 4 0 ~ \mathrm { n m }$ (or $3 2 0 ~ { \mathfrak { n m } }$ ) and emission central wavelength of $4 0 5 ~ \mathrm { n m }$ .The fluorescence of each sample is proportional to the conccntration of galactose in the sam ple.

# Intended use

The Neonatal Total Galactose kit is intended for the quantitative determination of total galactosc (galactose and galactose-1-phosphatc) conccntrations in blood spccimcns dricd on filter paper as an aid in scrcening ncwborns for galactosemia.

# Substantial Equivalence

# Device Comparison

The following table compares the Neonatal Total Galactose kit with the predicate device.

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate Device</td><td colspan="1" rowspan="1">New Device</td></tr><tr><td colspan="1" rowspan="1">Device characteristies</td><td colspan="1" rowspan="1">BioRad Quantase Total GalactoseScreening Assay</td><td colspan="1" rowspan="1">Perkin Elmer Neonatal Total Galactose Kit</td></tr><tr><td colspan="3" rowspan="1">Device Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The Quantase™ Neonatal TotalGalactose Screening Assay isintended for use as a screeningmethod for measuring the totalD(+)galactose concentrations innewborn blood spot specimens.</td><td colspan="1" rowspan="1">The kit is intended for the quantitativedetermination of total galactose (galactoseand galacatose-1-phosphate)concentrations in blood specimens driedon filter paper as aid in screeningnewborns for galactosemia.</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Enzymatic assay</td><td colspan="1" rowspan="1">The same</td></tr><tr><td colspan="1" rowspan="1">Kit content</td><td colspan="1" rowspan="1">Calibrators/Standards, Controls andEnzymatic Reagents</td><td colspan="1" rowspan="1">The same, plus Assay Plates</td></tr><tr><td colspan="1" rowspan="1">Specimen type</td><td colspan="1" rowspan="1">Newborn dried blood spot specimens</td><td colspan="1" rowspan="1">The same</td></tr><tr><td colspan="1" rowspan="1">Interpretation ofresults</td><td colspan="1" rowspan="1">Standard curve</td><td colspan="1" rowspan="1">The same</td></tr><tr><td colspan="1" rowspan="1">Calibrator format</td><td colspan="1" rowspan="1">Dried blood spots</td><td colspan="1" rowspan="1">The same</td></tr><tr><td colspan="1" rowspan="1">Number of Controls</td><td colspan="1" rowspan="1">Two</td><td colspan="1" rowspan="1">The same</td></tr><tr><td colspan="1" rowspan="1">Control format</td><td colspan="1" rowspan="1">Dried blood spots</td><td colspan="1" rowspan="1">The same</td></tr><tr><td colspan="3" rowspan="1">Device Differences</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Colorimetric end point method</td><td colspan="1" rowspan="1">Prompt Fluorescence</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">Plate reader</td><td colspan="1" rowspan="1">Victor2 TM D Fluoromcter or equivalent</td></tr><tr><td colspan="1" rowspan="1">Calibrators/standards:Number of levels</td><td colspan="1" rowspan="1">Five(Four standard levels + Standard 0which is plain white paper)</td><td colspan="1" rowspan="1">Six(six calibrator levels)</td></tr><tr><td colspan="1" rowspan="1">Analytical sensitivity</td><td colspan="1" rowspan="1">0.60 mg/dL</td><td colspan="1" rowspan="1">1.3 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Linearity</td><td colspan="1" rowspan="1">0.6 to 55 mg/dL</td><td colspan="1" rowspan="1">1.3 to 56 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">0.6 to 50 mg/mL</td><td colspan="1" rowspan="1">1.3 to 40 mg/mL</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Mean total galactose concentration1.05 mg/dL (n=462) measured with apunch size of 3/16".</td><td colspan="1" rowspan="1">Median total galactose concentration,1.7 mg/dL (n=2109) mcasured with a punchsize of 1/8".</td></tr><tr><td colspan="1" rowspan="1">Specificity/Recovery</td><td colspan="7" rowspan="1">Mean recovery of D(+) galactose inthe prcsense of 100mg/dL of thefollowing sugars and D(+)galactosemetabolites was 95.07% (S:D:7.49%).D-(+)-Gucoseα-LactoseD(-)FructoseSucroseMaltoseD(+)MannoseD-MannitolGalactitolD-Galacturonic AcidD-Glucuronic AcidD(-)Ribose</td><td colspan="5" rowspan="1">Mean recovery of galactose in the presence ofgalactose, galactose-1-phosphate or galactose+ galactose-1-phosphate was 79 - 81 %.</td></tr><tr><td colspan="1" rowspan="1">Interference</td><td colspan="7" rowspan="1">No interference observed withknown antibiotics, non-antibioticsand metabolites</td><td colspan="5" rowspan="1">No interference with glucosc, mannose,fructose, ascorbate, bilirubin, hemoglobin,protein BSA and acetaminophen. Glutathione(60 mg/dL.) and lipemic samples (0.25 -1g/dL) interfere with the assay.</td></tr><tr><td colspan="8" rowspan="14">Precision                 Intra-assay (1/8 punch size)Mean D(+)   % CV    nGalactoseconc.(mg/dL)1.06           13.99    206.81           10.02    2014.23         6.67     2033.96         3.94     20Total Assay (1/8 punch size)Mean D(+)    % CV  nGalactoseconc.(mg/dL)1.43           17.42   396.97           6.27    4014.53          7.43     4033.58         8.53    40</td><td colspan="4" rowspan="1">Intra-assay (1/8 punch size)</td><td colspan="1" rowspan="1">Intra-assay and total variation</td></tr><tr><td colspan="1" rowspan="1">Mean D(+)Galactoseconc.(mg/dL)</td><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">n</td><td colspan="3" rowspan="1"></td><td colspan="2" rowspan="1">MeanGalactoseconc.(mg/dL)</td><td colspan="1" rowspan="1">Intra-assay(%CV)</td><td colspan="1" rowspan="1">Totalvariation(%CV)</td><td colspan="1" rowspan="1">n</td></tr><tr><td colspan="1" rowspan="1">1.06</td><td colspan="1" rowspan="1">13.99</td><td colspan="1" rowspan="1">20</td><td colspan="2" rowspan="1"></td><td></td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">12.3</td><td colspan="1" rowspan="1">143</td></tr><tr><td colspan="1" rowspan="1">6.81</td><td colspan="1" rowspan="1">10.02</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1"></td><td></td><td colspan="1" rowspan="1">13.8</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">10.8</td><td colspan="1" rowspan="1">144</td></tr><tr><td colspan="1" rowspan="1">14.23</td><td colspan="1" rowspan="1">6.67</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1"></td><td></td><td colspan="1" rowspan="1">20.2</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">8.6</td><td colspan="1" rowspan="1">144</td></tr><tr><td colspan="1" rowspan="1">33.96</td><td colspan="1" rowspan="1">3.94</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">−</td><td></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td></td><td colspan="1" rowspan="2">MeanGalactoseconc.(mg/dL)</td><td colspan="1" rowspan="2">Intra-assay(%CV)</td><td colspan="1" rowspan="2">Totalwithin lotvariation(%CV)</td><td colspan="1" rowspan="2">n</td></tr><tr><td colspan="1" rowspan="3">Mean D(+)Galactoseconc.(mg/dL)</td><td colspan="1" rowspan="3">% CV</td><td colspan="1" rowspan="3">n</td><td colspan="3" rowspan="3"></td><td></td></tr><tr><td></td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">7.8</td><td colspan="1" rowspan="1">12.7</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="3" rowspan="1"></td><td></td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">7.2</td><td colspan="1" rowspan="1">11.8</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">1.43</td><td colspan="1" rowspan="1">17.42</td><td colspan="1" rowspan="1">39</td><td colspan="2" rowspan="1"></td><td></td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">6.0</td><td colspan="1" rowspan="1">8.4</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">6.97</td><td colspan="1" rowspan="1">6.27</td><td colspan="1" rowspan="1">40</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1"></td><td></td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">8.6</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">14.53</td><td colspan="1" rowspan="1">7.43</td><td colspan="1" rowspan="1">40</td><td colspan="3" rowspan="1"></td><td colspan="3" rowspan="2"></td><td colspan="4" rowspan="2"></td></tr><tr><td colspan="1" rowspan="1">33.58</td><td colspan="1" rowspan="1">8.53</td><td colspan="1" rowspan="1">40</td></tr></table>

# Method Comparison

Thc PerkinElmer Neonatal Total Galactose kit (y) was compared with the BioRad Quantase™ Neonatal Total Galactose Screening Assay $( 1 5 9 9 0 6 5 4 )$ . using routine newborn screening dried blood spot specimens in the range of $7 2 \ \mu \mathrm { m o l / L }$ to $1 9 7 0 \ \mu \mathrm { m o l / L }$ $\mathrm { 1 . 3 { - } 3 5 . 5 ~ m g / d L } .$ (determined with the PerkinElmer kit). The correlation was found to be:

$$
y = 0 . 6 5 \mathrm { x } + 1 . 7 3 , ~ \mathrm { r } = 0 . 8 7 ~ ( \mathrm { n } = 8 4 2 )
$$

The total galacose cut-o values by pcrctil or both the PerkinElmerNeonatal Total Galactose kit nd the predicatc wcre determined by analyzing 2109 routine newborn screening dried blood spol specimens reprecnting an US population. The results are shown in the table below:

<table><tr><td rowspan=1 colspan=5>Total galactose cut-off values by percentile</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>PerkinElmcr kit</td><td rowspan=1 colspan=2>Predicate</td></tr><tr><td rowspan=1 colspan=1>μmol/L</td><td rowspan=1 colspan=1>mg/dL</td><td rowspan=1 colspan=1>μmol/L</td><td rowspan=1 colspan=1>mg/dL</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>95thpercentilc</td><td rowspan=1 colspan=1>283</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>97.5thpercentile</td><td rowspan=1 colspan=1>355</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>316</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>99thpercentile</td><td rowspan=1 colspan=1>461</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>521</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>99.5thpercentile</td><td rowspan=1 colspan=1>549</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>678</td><td rowspan=1 colspan=1>12.2</td></tr></table>

The screening summaries using the $9 5 ^ { \mathrm { t h } }$ and $9 9 ^ { \parallel }$ percentiles are presented in the tables below. The samples used in the study, representing an US population, included 2116 newborn dri blood samples (2109 routie sceeig specimens and seven restrospective specimens of which hree were diagnosed true positives for galactosmia).

In the tabls bclow he screening psiives $( + )$ are samples $\geq$ cut-off and the sceeig eves $( - )$ are samples $<$ cut-off.

<table><tr><td rowspan=1 colspan=5>Screening summary using the 95&quot; percentile</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>PerkinElmer kit</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Diagnosedgalactosemia</td><td rowspan=1 colspan=1>No diagnosedgalactosemia</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1956</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1956</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2116</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2113</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Screening summary usingthe 95th percentile</td><td rowspan=1 colspan=3>Predicate</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>PerkinElmer kit</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>119</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>1956</td><td rowspan=1 colspan=1>1997</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>2002</td><td rowspan=1 colspan=1>2116</td></tr></table>

When the $9 5 ^ { \mathrm { t h } }$ percentile was used as a cut-off for both methods, the positive percent agreement was $6 4 \%$ (73/1 14) and the overall percent agreement was $9 5 . 9 \%$ $( 7 3 + 1 9 5 6 ) / 2 1 1 6 )$ .

<table><tr><td rowspan=1 colspan=5>Screening summary using the 99th percentile</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>PerkinElmer kit</td><td rowspan=1 colspan=1>Totalsubjects</td><td rowspan=1 colspan=1>Diagnosedgalactosemia</td><td rowspan=1 colspan=1>No diagnosedgalactosemia</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+ra}$</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2078</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2078</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>canmaGeow</td><td rowspan=1 colspan=1>2116</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2113</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Screening summary usingthe 99th percentile</td><td rowspan=1 colspan=3>Predicate</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>PerkinElmer kit</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2078</td><td rowspan=1 colspan=1>2086</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>2087</td><td rowspan=1 colspan=1>2116</td></tr></table>

When the $9 9 ^ { \mathrm { t h } }$ percentile was uscd as a cut-off for both methods, the positive percent agreement was $7 2 . 4 \%$ (21/29) and the overall percent agreement was $9 9 . 2 \%$ $( 2 1 + 2 0 7 8 ) / 2 1 1 6 )$ +

The total glactose concentrations of the three true galactosemia specimens used in the study weeas shownin the table below:

<table><tr><td rowspan=1 colspan=3>Total Galactose concentrations of true positive specimens</td></tr><tr><td rowspan=1 colspan=1>Specimen no.</td><td rowspan=1 colspan=1>PerkinElmer kit(mg/dI)</td><td rowspan=1 colspan=1>Commercially available kit(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>23.9</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>14.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>22.2</td><td rowspan=1 colspan=1>39.1</td></tr></table>

Wallac Oy c/o Ms. Helena Lundstrom Regulatory Affairs Manager Mustionkatu 6, PO Box 10 Turku 20750, Finland

Re: k071649 Trade/Device Name: Neonatal Total Galactose Kit Regulation Number: 21 CFR 862.1310 Regulation Name: Galactose Test System Regulatory Class: Class I Product Code: JIA Dated: July 21, 2008 Received: July 24, 2008

Dear Ms. Lundstrom:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Ac cthatot requie pproval  preare apvl pplitn MA).o y, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class Ⅱ (Special Controls) or class ⅢI (MA), it may be subject to such additional controls. Existing major regulations affcting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with a e Act' requrmets, including, but not limite to:reistraton and listing (1 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter willallow you to begin marketing your device as described in your Section 510(k) pofinl equvec orevi y marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tol-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.COopes, M.S. D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indication for Use

510(k) Number (if known): k071649

Device Name: Neonatal Total Galactose Kit

Indication For Use:

This kit is intended for the quantitative determination of total galactose (galactose and galactose-1-phosphate) concentrations in blood specimens dried on filter paper as an aid in screening newborns for galactosemia.

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/a5cd3bd13062b7b97c066fb90bb421e31069aecc59fefbfd3a8688b590a9ade9.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k)_k071649